One interim signal has carried Laminar Pharma’s LAM561 program far enough to reach a full enrollment close, and the statistical design now does the waiting. The Spanish biotech announced last week that its 144-patient, randomized, placebo-controlled Phase 2b/3 trial in newly diagnosed glioblastoma has completed its last patient, last visit, with topline overall survival data expected in the second quarter of 2027. That timeline is set by a pre-specified trigger: the OS analysis fires once 90 survival events accumulate, a threshold the trial has already reached, making the Q2 2027 readout a function of data lock and analysis rather than patient follow-up.
The clinical context matters here. Temozolomide plus radiotherapy became the backbone of newly diagnosed GBM treatment in 2005, and median overall survival has hovered around 14.5 months ever since despite subsequent additions to the therapeutic arsenal. The MGMT-methylated subgroup has always been the population where incremental gains look most plausible: the five-year EORTC/NCIC analysis placed median OS at 23.4 months for methylated patients versus 12.6 months for unmethylated patients, establishing a biologically distinct cohort that responds meaningfully to temozolomide. Laminar’s interim unblinded data, released in March 2025 after the independent data monitoring committee recommended continuing without modification, flagged a potentially clinically relevant PFS improvement specifically in MGMT-methylated patients on LAM561 plus standard of care. That subgroup signal is now the trial’s most consequential variable heading into the OS read.
LAM561 is an oral synthetic derivative of oleic acid that targets plasma membrane lipid composition in cancer cells rather than a conventional receptor or kinase pathway. The mechanism is sufficiently distinct that early-phase data in refractory glioma established tolerability without the dose-limiting toxicities that have derailed several CNS programs, and the 144-patient Phase 2b/3 population showed a safety profile consistent with those earlier findings. The compassionate use program now active for patients who demonstrated clinical benefit extends the real-world evidence base and signals enough physician confidence to sustain treatment past protocol completion, which itself carries some interpretive weight ahead of a regulatory submission.
The single number to hold is the OS event count relative to the 90-event trigger. If survival curves in the MGMT-methylated arm separate with the same directionality seen in the PFS interim, Laminar will face a straightforward path to a European submission given its Mallorca headquarters and the continent’s roughly 25,000 annual incident cases. If the OS data fail to confirm the PFS signal, the subgroup hypothesis dissolves and the membrane lipid therapy platform loses its lead clinical proof point. Everything in 2027 pivots on that one survival curve.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
